Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12790862 | 1.00 | AKT1 (0.35) | AKT1SLC6A2SLC6A4SLC6A3USP2 | |
| SCHEMBL17771740 | 0.84 | AKT1 (0.38) | AKT1SLC6A2SLC6A4SLC6A3USP2 | |
| SCHEMBL17771698 | 0.84 | AKT1 (0.38) | AKT1SLC6A2SLC6A4SLC6A3USP2 | |
| SCHEMBL12790804 | 0.84 | AKT1 (0.47) | AKT1SLC6A2SLC6A4SLC6A3USP2 | |
| SCHEMBL12847765 | 0.80 | GRIA2 (0.37) | AKT1SLC6A2SLC6A4SLC6A3USP2 | |
| SCHEMBL12847353 | 0.80 | GRIA2 (0.37) | AKT1SLC6A2SLC6A4SLC6A3USP2 | |
| SCHEMBL12790855 | 0.79 | CYP2C9 (0.36) | AKT1SLC6A4ALDH1A1OPRM1OPRK1 | |
| SCHEMBL12790852 | 0.77 | NOTUM (0.42) | AKT1SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL3666216 | 0.77 | NOTUM (0.42) | AKT1SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL12791831 | 0.73 | KMT2A (0.34) | SLC6A3OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346805-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324221-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | AKT1 1/4885SLC6A2 2592/4885SLC6A4 2455/4885 |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, AKT2 | AKT1 2/4885SLC6A2 2139/4885SLC6A4 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.